TIDMOPTI

RNS Number : 5753T

OptiBiotix Health PLC

21 March 2023

OptiBiotix Health plc

("OptiBiotix" or the "Company")

21 March 2023

Change of Broker

OptiBiotix Health p lc (AI M: OPTI), a life sciences busi ness d eveloping compou n ds to tackle obesity, cardiovascular disease, diabetes and skincare, a nnounces that the Company gave three months' notice to its joint broker Cenkos Securities plc on 28 December 2022. As of 28 March 2023, that notice will be served and Cenkos will cease to be the Company's joint broker.

Peterhouse Capital will remain as the Company's sole broker.

The Directors of the Company are responsible for the release of this announcement.

For further information, please contact:

 
  OptiBiotix Health plc                              www.optibiotix.com 
  Neil Davidson, Chairman                          Contact via Walbrook 
                                                                  below 
  Stephen O'Hara, Chief Executive 
 
  Cairn Financial Advisers LLP (NOMAD)               Tel: 020 7213 0880 
  Liam Murray / Jo Turner / Ludovico Lazzaretti 
 
  Peterhouse Capital Limited (Broker)                Tel: 020 7220 9797 
  Duncan Vasey / Lucy Williams 
  Walbrook PR Ltd                                    Mob: 07876 741 001 
  Anna Dunphy 
 
 
   About OptiBiotix   -   www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

APPSEFFMSEDSEID

(END) Dow Jones Newswires

March 21, 2023 03:00 ET (07:00 GMT)

OptiBiotix Health (AQSE:OPTI.GB)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024 Haga Click aquí para más Gráficas OptiBiotix Health.
OptiBiotix Health (AQSE:OPTI.GB)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024 Haga Click aquí para más Gráficas OptiBiotix Health.